$TransMedics Group, Inc.(TMDX)$
Needham Upgrades $TMDX to Buy from Hold, Sets PT at $148
Analyst comments: "Our transplant tracker now indicates that TMDX’s U.S. sales are likely to beat consensus in 3Q25 based on the latest SRTR data. Additionally, we expect TMDX’s new heart and lung clinical trials and its international expansion to become increasing growth drivers during 2026.
TMDX’s margins are also increasing rapidly, and we expect meaningful EPS upside. Competition remains a potential risk, but we believe TMDX holds a significant lead in a still largely underpenetrated market."
Analyst: Mike Matson
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments